Eris Lifesciences is planning to set up a manufacturing facility in Gujarat. The facility, estimated to be about 10 times the size of Eris’ existing facility at Guwahati, will be developed in a phased manner, with Phase-I investments of Rs 120-130 crore.
The new plant is likely to be commissioned by the end of FY23.
The Guwahati facility in Assam is spread over 1,00,000 sq ft built-up area and carries WHO-GMP certification. The tablets block at the facility has reached 60 percent capacity utilisation and the company projects it to reach 80 percent in the next three years.